Results 11 to 20 of about 20,176 (178)

Rosuvastatin

Reactions Weekly
Bajaj T, Patel P, Giwa AO.
europepmc   +8 more sources

Rosuvastatin is Superior Compared to Simvastatin and Atorvastatin to Induce Endothelial Progenitor Cells Migration [PDF]

Journal of Clinical and Diagnostic Research, 2019
Introduction: Statins have shown to improve Endothelial Progenitor Cells (EPCs) function, however no comparison has been done between various statins effectivity to induce EPCs migration.
Yudi Her Oktaviono, Makhyan Jibril Al Farabi, Feranti Meuthia, Tyagita Verdena Rani Savitri, Djoko Soemantri   +4 more
doaj   +1 more source

Evaluation of rosuvastatin-induced QT prolongation risk using real-world data, in vitro cardiomyocyte studies, and mortality assessment

Scientific Reports, 2023
Drug-induced QT prolongation is attributed to several mechanisms, including hERG channel blockage. However, the risks, mechanisms, and the effects of rosuvastatin-induced QT prolongation remain unclear.
Yeryung Koo, Sung-Ae Hyun, Byung Jin Choi, Yujeong Kim, Tae Young Kim, Hong-Seok Lim, Joung-Wook Seo, Dukyong Yoon   +7 more
doaj   +1 more source

Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study

Cardiovascular Diabetology, 2005
Objective The Use of Rosuvastatin versus Atorvastatin iN type 2 diabetes mellitUS (URANUS) study compared rosuvastatin with atorvastatin for the reduction of low-density lipoprotein cholesterol (LDL-C) in patients with type 2 diabetes.
Berne Christian, Siewert-Delle Annica
doaj   +1 more source

EFFECTS OF ROSUVASTATIN IN EXPERIMENTALLY-INDUCED CARDIAC ISCHEMIA AND ON AORTIC VASCULAR REACTIVITY. [PDF]

Al-Azhar Journal of Pharmaceutical Sciences, 2017
Myocardial infarction (MI) continues to be a major public health problem in the world. The present study aimed to elucidate the protective effect of  different doses  of rosuvastatin and cilostazol, as well as their combination on isoprenaline-induced MI
Maryam Hamouda
doaj   +1 more source

No Effect of Digoxin on Rosuvastatin Pharmacokinetics in Healthy Subjects: Utility of Oita Combination for Clinical Drug–Drug Interaction Study

Clinical and Translational Science, 2019
This study evaluated the utility of combination of digoxin (0.25 mg) and rosuvastatin (5 mg) as a new transporter (P‐glycoprotein/breast cancer resistance protein/organic anion‐transporting polypeptide (OATP)1B1/OATP1B3) probe cocktail (Oita combination)
Naoyuki Otani, Hirokazu Wakuda, Hiromitsu Imai, Masae Kuranari, Yasuyuki Ishii, Yuko Ito, Akihiro Okubo, Osamu Ogawa, Kenji Takeda, Tetsuji Ohyama, Tomoko Hasunuma, Naoto Uemura   +11 more
doaj   +1 more source

Dual Effect of Rosuvastatin on Glucose Homeostasis Through Improved Insulin Sensitivity and Reduced Insulin Secretion

EBioMedicine, 2016
Statins are beneficial in the treatment of cardiovascular disease (CVD), but these lipid-lowering drugs are associated with increased incidence of new on-set diabetes.
Vishal A. Salunkhe, Inês G. Mollet, Jones K. Ofori, Helena A. Malm, Jonathan L.S. Esguerra, Thomas M. Reinbothe, Karin G. Stenkula, Anna Wendt, Lena Eliasson, Jenny Vikman   +9 more
doaj   +1 more source

The impact of rosuvastatin on inflammatory markers in L-NAME induced hypertensive rats

Zanco Journal of Medical Sciences, 2023
Background and objective: Many clinical trials have revealed that HMG-CoA reductase inhibitors (statins) have anti-inflammatory effects through their pleiotropic activities there by decreasing the risk of cardiovascular disease (CVD). This study intended
Kawa F. Dizaye, Begard O. Berzinji
doaj   +1 more source

Tranexamic acid and rosuvastatin in patients at risk of cardiovascular events after noncardiac surgery: a pilot of the POISE-3 randomized controlled trial

Pilot and Feasibility Studies, 2020
Background Surgical bleeding is associated with postoperative cardiovascular complications. The efficacy and safety of tranexamic acid (TXA) in noncardiac surgery are still uncertain. Statins may prevent perioperative cardiovascular complications.
Maura Marcucci, Emmanuelle Duceppe, Yannick Le Manach, Clive Kearon, John W. Eikelboom, Kayla Pohl, Jessica Vincent, Saeed Darvish-Kazem, Sadeesh K. Srinathan, John D. D. Neary, Joel L. Parlow, Andrea Kurz, Peter L. Gross, Marko Mrkobrada, Kumar Balasubramanian, Daniel I. Sessler, P. J. Devereaux   +16 more
doaj   +1 more source

Determination of a “Specific Population Who Could Benefit From Rosuvastatin”: A Secondary Analysis of a Randomized Controlled Trial to Uncover the Novel Value of Rosuvastatin for the Precise Treatment of ARDS

Frontiers in Medicine, 2020
Background: The high heterogeneity of acute respiratory distress syndrome (ARDS) contributes to paradoxical conclusions from previous investigations of rosuvastatin for ARDS.
Shi Zhang, Zhonghua Lu, Zongsheng Wu, Jianfeng Xie, Yi Yang, Haibo Qiu   +5 more
doaj   +1 more source